Eastern Cooperative Oncology Group
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2012-01-01
- Employees
- 51
- Market Cap
- -
- Website
- https://ecog-acrin.org
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial
Completed
- Conditions
- LymphomaLeukemia
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 1873
- Registration Number
- NCT00897767
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸Tufts Medical Center Cancer Center, Boston, Massachusetts, United States
Studying Tumor Tissue Samples to Learn More About DNA Changes and Response in Patients With Breast Cancer Treated With Bevacizumab on Clinical Trial ECOG-2100
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 500
- Registration Number
- NCT00899418
Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy
Completed
- Conditions
- Her-2PgrBreast CancerEstrogen Receptor
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 900
- Registration Number
- NCT00897299
Study of Bone Marrow Samples From Patients With Acute Leukemia
Completed
- Conditions
- Leukemia
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 40
- Registration Number
- NCT00897559
Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
Completed
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 33
- Registration Number
- NCT00899080
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
Phase 2
Withdrawn
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00771017
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 81
- Registration Number
- NCT00700882
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, United States
🇺🇸Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States
Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer
Phase 2
Withdrawn
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00685633
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Phase 2
Terminated
- Conditions
- Esophageal Cancer
- Interventions
- Procedure: SurgeryRadiation: Radiotherapy
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 22
- Registration Number
- NCT00551759
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Hematology and Oncology Associates, Chicago, Illinois, United States
🇺🇸Southwest Medical Center, Liberal, Kansas, United States
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
Not Applicable
Withdrawn
- Conditions
- Cancer
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00499291
© Copyright 2025. All Rights Reserved by MedPath